Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06461156 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Start date: Jul 22, 2025 to Jun 26, 2024v3
  2. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Jun 30, 2024 to Jul 22, 2025 · Study sites: 0 to 1v2 Show 2 more changesShow less
    • Start date changed from estimate of Jun 30, 2024 to Jul 22, 2025
    • Study sites: 0 to 1
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
HS-10504 is a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR C797S mutation. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10504 in Chinese locally advanced or metastatic NSCLC.
Trial Details
NCT Number NCT06461156
Lead Sponsor Jiangsu Hansoh Pharmaceutical Co., Ltd.
Conditions Locally Advanced or Metastatic NSCLC
Enrollment 230 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov